CHRISTA SOEKAMTO, M.D.
Ophthalmology Physician · SCHERTZ, TX
Individual Active NPI 1558725697
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 951 | 24,411 | $10,652,020 | $3,296,500 | $2,602,690 |
| 2023 | 671 | 8,929 | $4,700,263 | $1,472,612 | $1,165,821 |
| 2022 | 200 | 879 | $578,976 | $187,079 | $143,993 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 13,380 | $34 | $27 |
| J0177 | Injection, aflibercept hd, 1 mg | 2,352 | $332 | $264 |
| 92134 | Imaging of retina | 2,051 | $41 | $31 |
| 67028 | Injection of drug into eye | 1,280 | $124 | $95 |
| J0178 | Injection, aflibercept, 1 mg | 1,222 | $826 | $657 |
| J2782 | Injection, avacincaptad pegol, 0.1 mg | 840 | $108 | $86 |
| 92014 | Established patient complete exam of visual system | 824 | $126 | $90 |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 795 | $234 | $186 |
| 92250 | Photography of the retina | 271 | $37 | $27 |
| 92004 | New patient complete exam of visual system | 267 | $148 | $107 |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 210 | $160 | $128 |
| J2778 | Injection, ranibizumab, 0.1 mg | 181 | $169 | $134 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | S5502 | TX |
| Internal Medicine Physician | 207R00000X | 2016022955 | MO | |
| Retina Specialist (Ophthalmology) Physician | 207WX0107X | S5502 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in Texas
- NPI 1205154291
- NPI 1295817609
- NPI 1417308149
- NPI 1629188073
- NPI 1649521873
- NPI 1700085248
- NPI 1366749343
- NPI 1972378941
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.